Clinical trial
A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®
NCT01187550 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- April 30, 2009
- Enrollment
- 214 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.